Patients with Cutaneous Leishmaniasis Cutaneous leishmaniasis, meglumine antimoniate, miltefosine, efficacy, safety
Conditions
Interventions
Patients were randomly allocated to either Group A or Group B, using the lottery method. Group A received meglumine antimoniate at a dose of 20 mg/kg. Follow-up assessments were conducted at 2 weeks,
Active Comparator Drug,Active Comparator Drug
Meglumine antimoniate,miltefosine combined with meglumine antimoniate
Sponsors
COMBINED MILITARY HOSPITAL QUETTA
Eligibility
Sex/Gender
All
Age
10 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1: Patients of both genders, 2: aged 10-65 years 3: biopsy-proven CL. 4: Multiple lesions on body 5: Lesions not responding to local treatment or meeting WHO guidelines 6: Lesions on lower legs, over a joint, mucosa or cartilage
Exclusion criteria
Exclusion criteria: 1: People with renal dysfunction, 2: hepatic impairment 3: cardiovascular issues 4: Immunocompromised patients 5: People with a known hypersensitivity or allergy to MA and/or miltefosine 6: Patients enrolled in other research protocols 7: Pregnant and breastfeeding women, and 8: Those who refused to accept the diagnostic procedures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical cure by week 8 8 weeks clinical response criteria | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug safety was analyzed by assessing frequency and severity of adverse effects 8 weeks clinical response criteria | — |
Countries
Pakistan
Contacts
Public ContactMehrunisa Khan
COMBINED MILITARY HOSPITAL QUETTA
Outcome results
None listed